Investing Ideas
/
Canadian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Canadian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Results

2 new

Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.

4 companies

Curaleaf Holdings

Market Cap: CA$3.6b

Engages in the retail and wholesale of cannabis products in the United States and internationally.

New

CURA

CA$13.73

5.7%

9.8%

Green Thumb Industries

Market Cap: CA$2.3b

Manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States.

New

GTII

CA$10.55

3.8%

-13.2%

Cronos Group

Market Cap: CA$1.7b

A cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.

CRON

CA$4.58

4.8%

27.2%

Cresco Labs

Market Cap: CA$516.0m

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany.

CA$1.13

4.6%

-38.9%